PharmExec Blog

Outlook “Gloomy” for TB Investment

The approval last year of Johnson & Johnson’s (J&J) treatment for tuberculosis (bedaquiline) — at the time the first TB drug approval in 40 years — “remains an exception to the generally gloomy outlook” for investment in TB R&D, writes Andrew Ward in this week’s Financial Times.

AstraZeneca’s decision in January to close a laboratory in India that was conducting early-stage research into TB is more typical of Big Pharma’s current approach to TB, says Ward.

TB is “particularly unattractive as a commercial proposition” because of its heavy concentration in poorer countries.

J&J is not expected to profit from bedaquiline, but the company has been “rewarded” by U.S. regulators for developing the TB treatment with a scheme enabling it to put a potentially more lucrative new drug through an accelerated review process.

Although, Ward points out, Japan’s  Otsuka has also since won provisional approval in Europe for its delamanid treatment for MDR-TB, few in Big Pharma are following the example of these companies.


This entry was posted in Emerging Markets, Global, Strategy and tagged , , , , , . Bookmark the permalink. Trackbacks are closed, but you can post a comment.

Post a Comment

Your email is never published nor shared. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

  • Categories

  • Meta